EUVIMEDEUVIMED entdecken
Crossref

Inhalable bionic nanoparticle vaccine mimicking pulmonary surfactant enhances anti-tuberculosis immunity

Yanqiu Wu, Weifeng Ma, Han Duan, Xinting Fu, Jiamei Wang, Chunhua Yang, Qin Gu, Yue Jia, Yunlong Zhang, Fei Ma, Zihui Wei, Bohua Ren und 4 weitere

European Cells & Materials · 29.05.2026 · 57

DOI: 10.22203/ecm.v057a03 ↗

Kurz gefasst

Fachartikel in der Zeitschrift European Cells & Materials, online erschienen am 29.05.2026. Verfasst von Yanqiu Wu und 15 weiteren Autor:innen.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Tuberculosis (TB), an infectious disease caused by Mycobacterium tuberculosis (M.tb), remains a formidable global public health threat. The currently available Bacillus Calmette-Guérin (BCG) vaccine, while effective in children, provides inadequate protection for adults, highlighting an urgent need for novel vaccine development.

Methods

This study constructed an inhalable biomimetic nanoparticle vaccine, designated ECQ@PS-LPs. The vaccine utilizes liposomes that mimic natural pulmonary surfactant as a carrier to co-encapsulate two key TB antigens, ESAT-6 and CFP-10, along with the immunoadjuvant QS-21. Following intranasal administration in mice, immune responses and protective efficacy were evaluated. Using one-way ANOVA with post-hoc testing, statistical significance was defined as *p < 0.05, **p < 0.01 and ***p < 0.001.

Results

The ECQ@PS-LPs vaccine effectively breached the alveolar surfactant barrier, significantly enhancing uptake by antigen-presenting cells. This triggered a robust multidimensional immune response, including potent cellular immunity (characterized by Th1 and Th17 responses), systemic humoral immunity (indicated by IgG production), and strong mucosal immunity (evidenced by sIgA). Furthermore, the vaccine induced durable immune memory, marked by the generation of tissue-resident memory T cells (TRM) and central memory T cells (TCM). In a M.tb challenge model, ECQ@PS-LPs conferred a level of protection comparable to the BCG vaccine and elicited a superior mucosal immune response. The vaccine formulation also demonstrated a simple preparation process and favorable biological safety profile.

Conclusions

ECQ@PS-LPs represents a promising inhalable candidate vaccine for TB. It effectively induces comprehensive and persistent immune protection, particularly at the mucosal site, offering a novel and strategic direction for preventing TB in adults.

Zitieren

APA

Wu, Y., Ma, W., Duan, H., Fu, X., Wang, J., Yang, C., Gu, Q., Jia, Y., Zhang, Y., Ma, F., Wei, Z., Ren, B., Wang, Q., Hei, Y., Ma, Q., & Li, B. (2026). Inhalable bionic nanoparticle vaccine mimicking pulmonary surfactant enhances anti-tuberculosis immunity. European Cells & Materials, 57. https://doi.org/10.22203/ecm.v057a03

Vancouver

Wu Y, Ma W, Duan H, Fu X, Wang J, Yang C, et al. Inhalable bionic nanoparticle vaccine mimicking pulmonary surfactant enhances anti-tuberculosis immunity. European Cells & Materials. 2026;57. doi:10.22203/ecm.v057a03

BibTeX
@article{Wu2026,
  author = {Wu, Yanqiu and Ma, Weifeng and Duan, Han and Fu, Xinting and Wang, Jiamei and Yang, Chunhua and Gu, Qin and Jia, Yue and Zhang, Yunlong and Ma, Fei and Wei, Zihui and Ren, Bohua and Wang, Qinqin and Hei, Yuehua and Ma, Qiang and Li, Bin},
  title = {Inhalable bionic nanoparticle vaccine mimicking pulmonary surfactant enhances anti-tuberculosis immunity},
  journal = {European Cells & Materials},
  year = {2026},
  volume = {57},
  doi = {10.22203/ecm.v057a03}
}
Kostenlos starten →